| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry
|
Giraud, Eline L.
|
|
|
44 |
5 |
p. 581-588
|
article
|
| 2 |
Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study
|
Ziad, Abdelkrim
|
|
|
44 |
5 |
p. 565-579
|
article
|
| 3 |
An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP)
|
Gossell-Williams, Maxine
|
|
|
44 |
5 |
p. 511-513
|
article
|
| 4 |
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals
|
van Hunsel, Florence
|
|
|
44 |
5 |
p. 589-600
|
article
|
| 5 |
Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
|
Trumbo, Henry
|
|
|
44 |
5 |
p. 611-613
|
article
|
| 6 |
Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events
|
Shah, Sonam N.
|
|
|
44 |
5 |
p. 601-607
|
article
|
| 7 |
Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
|
Auerbach, Michael
|
|
|
44 |
5 |
p. 609-610
|
article
|
| 8 |
Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride
|
Ruigómez, Ana
|
|
|
44 |
5 |
p. 541-551
|
article
|
| 9 |
Population-Based Observational Study of Adverse Drug Event-Related Mortality in the Super-Aged Society of Japan
|
Funahashi, Tomoko
|
|
|
44 |
5 |
p. 531-539
|
article
|
| 10 |
Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study
|
Bulcock, Alexander
|
|
|
44 |
5 |
p. 553-564
|
article
|
| 11 |
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
|
Conaghan, Philip G.
|
|
|
44 |
5 |
p. 515-530
|
article
|
Journal description